Efficacy and safety of original EGFR-TKI combined with bevacizumab in advanced lung adenocarcinoma patients harboring EGFR-mutation experiencing gradual progression after EGFR-TKI treatment: a single-arm study

BACKGROUND: Keeping on original epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment is the standard treatment for gradual progression EGFR-positive metastatic non-small cell lung cancer (NSCLC). Angiogenic pathway can lead to EGFR-TKI resistance, but the effectiveness of...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Jianlin, Lei, Shuangyi, Wu, Zhijuan, Xiong, Shuanglong, Wang, Chunmei, Huang, Lumi, Liang, Guanzhong, Yang, Dan, Teng, Yan, Li, Yongsheng, Qi, Jun, Li, Dairong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843351/
https://www.ncbi.nlm.nih.gov/pubmed/36660644
http://dx.doi.org/10.21037/atm-22-6101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843351/
https://www.ncbi.nlm.nih.gov/pubmed/36660644
http://dx.doi.org/10.21037/atm-22-6101

Ejemplares similares